Biochemical and Biophysical Research Communications
Versatile Pt NCs-based chemotherapeutic agents significantly induce the apoptosis of cisplatin-resistant non-small cell lung cancer
Graphical abstract
Pt NCs-based chemotherapeutic agent can significantly inhibit proliferation of NSCLC cells compared to cisplatin and specifically promote cell apoptosis for both A549 and drug-resistant A549/DDP cells, exhibiting the great potential and advantages in the diagnosis and treatment of NSCLC.
Introduction
In the past decades, the incidence of lung cancer emerges an increasing trend along with air pollution and smoking which seriously affects the human survival. Lung cancer, as one of malignant cancers with high incidence, can divided into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [1,2]. In general, NSCLC accounts for nearly 85% among all lung cancer diagnoses [3]. Surgical treatment of lung cancer is the main and effective method for the non-metastatic and early stage lung cancer, but more than two-thirds of lung cancer patients have been already diagnosed as the advanced or metastatic cancer when it was found. Chemotherapy is one of the important adjuvant therapies for lung cancer patients, which can achieve an effective palliation. Accompanying with the increase of chemotherapy drug resistance rate, the treatment of traditional chemotherapy was confronted with the technological barrier. Therefore, more potential therapeutic strategies were explored based on the cancer molecular biology, including targeting epidermal growth factor receptor (EGFR) and other signal transduction and angiogenesis pathways [4,5]. As the development of molecular profiling technology in these years, targeted therapies bring hope to various refractory lung cancer patients, which has become an innovative breakthrough in the traditional treatment of lung cancer. Regretfully, targeted therapies have not demonstrated a survival advantage in stage IV diseases via many randomized trials, even though this kind of treatments have improved survival and quality of patients distinctly [6]. Compared with targeted therapy, chemotherapy has a wider therapeutic range and better price for lung cancer patients.
Platinum (Pt) stepped into the anti-cancer drugs when it was authorized by Food and Drug Administration (FDA) in 1978, and was revealed the remarkable curative effects in cancer therapy [[7], [8], [9], [10], [11], [12]]. Nonetheless, cisplatin (in Pt +2 state), as a representative drug, possesses a number of disadvantages which weakens their therapeutic efficiency through resulting in the ototoxicity, nephrotoxicity, neurotoxicity and myelosuppression [[13], [14], [15]]. Besides, various cancers, like colorectal, prostate and breast cancer, are essential insensitive to cisplatin, while others (e.g. testicular and ovarian cancer) may emerge the resistance to cisplatin after several cycles of therapy even though these cancer cells show sensitivity, stability and efficacy at the beginning stage [[16], [17], [18]]. As for the lung cancer, cisplatin-resistance is one of the most common and intractable problems during the clinical treatment of NSCLC on account of multiple mechanism such as lack of effective drug concentration in tumor cells, reduction of drug activity, DNA repair pathways, cell apoptosis changes, and so on [19]. Some genomics studies indicated that the mutation, translocation, missing, amplification and epigenetic change of protein-coding genes or promoter area, microRNA expression changes could lead to the drug-resistance of tumor [20]. Moreover, the phenotype of tumor drug-resistance is related to the change of multiple signal pathways. At present, taxanes, gemcitabine, vinorelbine and irinotecan, have been utilized in the first-line treatment of NSCLC as the alternative for cisplatin, however, the overall effect of chemotherapy cannot be well realized, or it is difficult to achieve the desired effect in the second treatment even if the initial treatment effect is satisfied. According to statistics, the combined chemotherapy efficiency of NSCLC is only 14–40%, and it is extremely easy to relapse. Thus, the new safe and effective Pt-based chemotherapeutic agents or novel way of delivering Pt-based agents are still need to explore consistently in order to overcome the serious problems like increasing incidence, complex disease, drug resistance, etc. [[21], [22], [23]] Recently, Pt nanoparticles (NPs) or nanoclusters (NCs), were applied in the Pt-based anticancer drug system and exhibited their potential to induce the apoptosis of several cancer cells [[24], [25], [26]]. Their apoptosis mechanism is owing to the rapid decomposition by intracellular acidic organelles and then the oxidation states of Pt trends to combine with DNA or proteins resulting in the DNA destroy. Xia et al. presented Pt nanocluster assembly could damage DNA through targeting disseminated hepatocellular carcinoma (HCC) tumor-initiating cancer stem-like cells (CSLCs) to achieve the effect of inhibiting tumor cell proliferation [27]. In our previous study, dual-functional Pt NCs-based anticancer materials were employed to biological image the blood system cells as fluorescent markers and selectively inhibit K562 and BV173 cancer cells through inducing the expression of pro-apoptotic proteins (p53, PUMA, and cleaved caspase) [15]. Until to now, it was not found Pt NPs- or NCs-based chemotherapeutic agents applied in the chemotherapy for NSCLC system.
Herein, we proposed polyethyleneimine-caged Pt NCs (PEI-caged Pt NCs) to use in the treatment of NSCLC, choosing the classical cisplatin-resistant A549/DDP cells and normal A549 cells as targets. These Pt NCs-based drugs could easily enter both A549 and A549/DDP cells achieving the biological imaging of NSCLC cells as fluorescent markers. Comparing with cisplatin, our Pt NCs-based chemotherapeutic agents significantly inhibited the proliferation of NSCLC cells, in addition, they also obviously induced the apoptosis in both A549/DDP and A549 cells. Most importantly, our agents showed the obvious entering behaviors for cell nucleus, superior inhibition and apoptosis effect on the cisplatin-resistance cells. Without adding any other fluorescent biomarkers, Pt NCs-based chemotherapeutic agents can overcome the problem of drug-resistance for NSCLC system, which exhibits the promising potential in the diagnosis and treatment of NSCLC.
Section snippets
Cell culture
Human lung adenocarcinoma (LAC) cells A549 were purchased from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). A549 resistance to DDP (A549/DDP) was brought from the SiXin Biotechnology Corporation Ltd. (Shanghai, China). A549/DDP cell resistance index (RI) was 4.51. After three times of cell reproduction, 2 μg/mL DDP should be added into the medium to maintain its resistance. All cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, GIBCO, New York, NY, USA) containing
Bio-imaging of NSCLC cells
The classical cisplatin-resistant A549/DDP cells and normal A549 cells were selected as targets to check the bio-imaging ability for Pt NCs-based drugs (Fig. 1a). The confocal microscopic images of A549 and A549/DDP cells labeled with Pt NCs-based chemotherapeutic agent are presented in Fig. 2. Both A549 and A549/DDP cells exhibit the red fluorescence signal that is emitted from our Pt NCs-based chemotherapeutic agent, while the cell nuclei are stained by DAPI showing the blue fluorescence.
Discussion
Based on the previous studies, specific DNA damages that induce apoptosis have been identified, which is one of the important routes of cell inactivation [22]. It is well known that P53 is a vital portion in the apoptotic response of cells, which induces transcriptional activation of pro-apoptotic factors such as recombinant factor related apoptosis (FAS), recombinant p53 upregulated modulator of apoptosis (PUMA) and Bcl-2 associated X protein (BAX) [28,29]. What has been confirmed is that a
Acknowledgements
This research was funded by National Natural Science Foundation of China (21807121), Key Scientific Research Projects of High Education of Henan Province (18A430005), Medical Science and Technology Project of Henan Province (201503133), and Project for Fundamental Research Funds of Zhongyuan University of Technology (K2018YY020). Dr. X. Huang gratefully acknowledges the support from “The 2019 Youth Talents Promotion Project of Henan Province”, “The 2018 Backbone Teachers of Zhongyuan University
References (30)
- et al.
MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin
Cancer Cell Int.
(2016) - et al.
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship
Mayo Clin. Proc.
(2008) - et al.
Tissue-penetrating delivery of compounds and nanoparticles into tumors
Cancer Cell
(2009) - et al.
Selective bio-labeling and induced apoptosis of hematopoietic cancer cells using dual-functional polyethylenimine-caged platinum nanoclusters
Biochem. Biophys. Res. Commun.
(2018) - et al.
Nanocarriers for delivery of platinum anticancer drugs
Adv. Drug Deliv. Rev.
(2013) - et al.
New mechanisms for old drugs: insights into DNA-unrelated effects of platinum compounds and drug resistance determinants
Drug Resist. Updates
(2015) Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs
Drug Resist. Updates
(2007)- et al.
Targeted delivery of platinum-based anticancer complexes
Curr. Opin. Chem. Biol.
(2013) - et al.
Platinum drugs: from Pt(II) compounds, Pt(IV) prodrugs, to Pt nanocrystals/nanoclusters
Sci. Bull.
(2017) - et al.
Involvement of Bcl-2 family, cytochrome c and caspase 3 in induction of apoptosis by beauvericin in human non-small cell lung cancer cells
Cancer Lett.
(2005)
Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells
FEBS Lett.
DNA damage-induced cell death by apoptosis
Trends Mol. Med.
Surgery for NSCLC in the era of personalized medicine
Nat. Rev. Clin. Oncol.
Improvement of survival for non-small cell lung cancer over time
OncoTargets Ther.
American society of clinical oncology treatment of unresectable non–small-cell lung cancer guideline: update 2003
J. Clin. Oncol.
Cited by (0)
- 1
These authors contributed equally to this work and should be considered as first authors.